NovaBridge To Move Vabysmo Follower Into Phase III Head-To-Head Trial

 
• By Dexter Jie Yan
  
Asia ophthalmology
VIS-101 will probably be pitted against Roche's Vabysmo in neovascular age-related macular degeneration (Shutterstock)

More from Clinical Trials

More from China